(NASDAQ:GSHD), – Total Revenue Increased 16% and Core Revenue* Grew 14% over the Prior-Year Period –– Total Written Premium increased 15% to $1.2 billion over the Prior-Year Period –– Net Income of $12.7 million versus Net Income of $12.6 million a year ago –– Adjusted EBITDA* of $29.7 million versus $26.1 million in the Prior-Year […]
(NASDAQ:VTYX), VTX3232 demonstrated significant reductions in cardiovascular risk factors, with additional benefits when combined with semaglutide VTX3232 monotherapy achieved ~80% reduction in hsCRP within the first week VTX3232 monotherapy reduced IL-6 levels at Week 12 below the threshold for cardiovascular risk of less-than or equal to1.65ng/L1 Statistically significant reductions in Lp(a) and liver inflammation No
(NYSE:KBR), NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of KBR, Inc. (NYSE: KBR). Shareholders who purchased shares of KBR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake
(NASDAQ:SVRA), NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of Savara Inc. (NASDAQ: SVRA). Shareholders who purchased shares of SVRA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake
Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors GlobeNewswire October 22, 2025 VTX3232 demonstrated significant reductions in cardiovascular risk factors, with additional benefits when combined with semaglutide VTX3232 monotherapy achieved ~80% reduction in hsCRP within the first week VTX3232 monotherapy reduced IL-6 levels
Savara Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before November 7, 2025 to Discuss Your Rights – SVRA GlobeNewswire October 22, 2025 NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of Savara Inc. (NASDAQ: SVRA). Shareholders who purchased
Contact The Gross Law Firm by November 18, 2025 Deadline to Join Class Action Against KBR, Inc.(KBR) GlobeNewswire October 22, 2025 NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of KBR, Inc. (NYSE: KBR). Shareholders who purchased shares of KBR during the class period listed
Goosehead Insurance, Inc. Announces Third Quarter 2025 Results GlobeNewswire October 22, 2025 – Total Revenue Increased 16% and Core Revenue* Grew 14% over the Prior-Year Period –– Total Written Premium increased 15% to $1.2 billion over the Prior-Year Period –– Net Income of $12.7 million versus Net Income of $12.6 million a year ago ––
Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report third quarter 2025 financial results on Wednesday, November 5, 2025, after the U.S. financial markets close. https://mma.prnewswire.com/media/1273133/Dynavax_Logo.jpg Dynavax will host a conference call and live audio webcast on Wednesday, November 5, 2025, at 4:30 p.m. ET/1:30 p.m. PT.
SEI Investments Company (NASDAQ:SEIC) today announced financial results for the third quarter 2025. Relative to the third quarter 2024, EPS increased by 9%, and revenue and operating income grew by 8% and 11%, respectively, with operating margin increasing to 28%. Consolidated Overview(In thousands, except For the Three Months For the Nine Monthsearnings per share) Ended